Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Not Recruiting

Trial ID: NCT00568633


Acute myeloid leukemia (AML) is a cancer of the bone marrow that mostly affects older adults. Even with the best chemotherapy, two-year disease-free survival is achieved in a minority of patients. Bone marrow transplantation from a sibling donor may improve cure rates; however, patients over 50 years of age have a high risk of complications and therefore generally are excluded from this treatment option. Recently our group developed a transplantation strategy for older cancer patients that protects against transplant-associated complications, yet does not interfere with the ability of the transplanted donor cells to destroy cancer cells. With this new method, we can now safely evaluate transplantation as a curative therapy for AML patients over the age of 50. We have assembled clinical and scientific researchers throughout the state of California to study and compare bone marrow transplantation using our new approach with the best standard of care chemotherapy in AML patients over the age of 50. The results of this study have the potential to establish a new treatment standard that will improve survival of older AML patients.

Official Title

A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission

Stanford Investigator(s)

Robert Lowsky
Robert Lowsky

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Jason Gotlib

Professor of Medicine (Hematology)

Sally Arai
Sally Arai

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Richard Hoppe
Richard Hoppe

Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology

Judith Shizuru
Judith Shizuru

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and of Pediatrics (Stem Cell Transplantation)

Laura Johnston
Laura Johnston

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Robert Negrin
Robert Negrin

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Wen-Kai Weng, MD, PhD
Wen-Kai Weng, MD, PhD

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology



   - ≥ 50 years of age and ≤ 75 years of age.

   - De novo acute myelogenous leukemia (AML), based on FAB and WHO criteria.

   - Intermediate or unfavorable cytogenetic abnormalities based on Southwest Oncology
   Group (SWOG) Cytogenetic Criteria.

   - First morphologic complete remission (CR), or CRp (a complete remission but with low
   platelets) following 1 or 2 courses of induction therapy, documented no more than 8
   weeks prior to the date of enrollment and confirmed at time of enrollment.

   - Karnofsky Performance Score ≥ 60.

   - Suitable for non-myeloablative transplantation or best treatment.

   - Able to understand and willing to sign a written informed consent document.


   - AML with favorable cytogenetic features based on SWOG Cytogenetic Criteria

   - AML, either treatment-related or MDS-related

   - Active CNS disease as identified by positive CSF cytospin at time of enrollment.

   - Prior or concurrent malignancies except localized non-melanoma skin malignancies or
   treated cervical carcinoma in situ. (EXCEPTION: Cancer treated with curative intent >
   5 years previously is allowed. EXCEPTION: Low grade lymphoma is allowed as long as
   active treatment is not required for control of disease)

   - Planned for allogeneic transplant using a full-dose conditioning

   - Life expectancy < 1 year due to diseases other than malignancy

   - Pregnant or breastfeeding.

   - HIV-seropositive.

   - Uncontrolled infection (presumed or documented) with progression after appropriate
   therapy for greater than one month.

   - Symptomatic coronary artery disease or uncontrolled congestive heart failure. Left
   ventricular ejection fraction (LVEF) is not required to be measured, however if
   measured, exclusion if ejection fraction is < 30%.

   - Requiring supplementary continuous oxygen. Diffusing capacity of the lungs for carbon
   monoxide (DLCO) is not required to be measured, however if it is measured, exclusion
   if DLCO < 35%.

   - Fulminant liver failure

   - Cirrhosis with evidence of portal hypertension or bridging fibrosis

   - Alcoholic hepatitis

   - Esophageal varices

   - A history of bleeding esophageal varices

   - Hepatic encephalopathy

   - Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the
   prothrombin time

   - Ascites related to portal hypertension

   - Chronic viral hepatitis with total serum bilirubin > 3 mg/dL

   - Symptomatic biliary disease


procedure: Allogeneic HSCT

drug: Anti-thymocyte globulin (ATG)

drug: Cyclosporine (CSP)

drug: Mycophenolate mofetil (MMF)

radiation: Total lymphoid irradiation (TLI)

drug: Methylprednisolone sodium succinate

drug: Best standard care

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals

New Trial Alerts

Receive email alerts when trials open to patients.